Financial Highlights: Management Indicators
- Operating Results and Plan
- Management Indicators
Management Indicators
(JPY million)
| FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | |
|---|---|---|---|---|---|
| Net sales | 76,480 | 76,565 | 86,789 | 80,849 | 80,471 |
| B&P | 16,409 | 16,864 | 17,544 | 18,583 | 15,469 |
| Healthcare | 29,390 | 26,924 | 31,905 | 34,713 | 36,690 |
| Creative Work | 5,345 | 5,485 | 6,278 | 6,746 | 5,880 |
| V&S | 10,403 | 8,665 | 8,337 | 9,269 | 10,043 |
| Amusement | 9,607 | 14,446 | 18,141 | 6,498 | 6,684 |
| Other | 5,324 | 4,179 | 4,581 | 5,039 | 5,702 |
| Operating income | 6,441 | 7,935 | 11,299 | 5,002 | 3,908 |
| Ordinary income | 6,597 | 8,814 | 12,110 | 6,126 | 6,326 |
| Net income attributable to owners of parent | 4,671 | 6,155 | 7,794 | 5,862 | 5,454 |
| Total assets | 125,284 | 150,061 | 155,459 | 155,935 | 164,819 |
| Shareholders' equity | 95,979 | 114,453 | 118,582 | 120,580 | 129,424 |
| Earnings per share (EPS)(JPY) | 219.13 | 288.71 | 365.61 | 280.97 | 265.13 |
| Book value per share (BPS)(JPY) | 4,501.78 | 5,368.29 | 5,562.01 | 5,861.22 | 6,290.09 |
| Cash dividends per share (JPY) | 110 | 115 | 120 | 125 | 200 |
| Total payout ratio (%) | 50.2 | 39.8 | 32.8 | 92.2 | 75.4 |
| Equity ratio (%) | 76.6 | 76.3 | 76.3 | 77.3 | 78.5 |
| ROE (%) | 4.9 | 5.9 | 6.7 | 4.9 | 4.4 |
| ROA (%) | 5.3 | 6.4 | 7.9 | 3.9 | 3.9 |
| PER (Times) | 14.4 | 14.5 | 9.8 | 14.6 | 19.6 |
| Cash flow from operating activities | 8,157 | 6,600 | 8,429 | △7,592 | 7,914 |
| Cash flow from investing activities | △3,717 | △3,333 | △2,394 | 853 | △1,057 |
| Cash flow from financing activities | △2,433 | △2,648 | △2,899 | △6,351 | △533 |
| Net increase (decrease) in cash and cash equivalents | 1,842 | 940 | 3,505 | △12,830 | 6,861 |
| Cash and cash equivalents, end of year | 17,942 | 18,882 | 22,387 | 9,557 | 16,418 |
| CAPEX | 4,346 | 3,563 | 3,033 | 3,163 | 2,390 |
| Depreciation | 2,986 | 3,033 | 2,612 | 2,307 | 2,672 |
| Research and development expenses | 5,993 | 5,642 | 5,834 | 6,142 | 6,314 |
| Ratio of research and development expenses to net sales (%) | 7.8 | 7.4 | 6.7 | 7.6 | 7.8 |
